Mesoblast Plans Small Trial After Second CRL For GVHD Cell Therapy

 
• By Joseph Haas

Seeking approval for pediatric patients with acute graft-versus-host disease, Mesoblast gets a second US FDA complete response and now says it will seek to get needed data from a small trial in adults.

FDA Complete response stamp holder
Mesoblast is planning new trial after second FDA complete response • Source: Nielsen Hobbs; the Pink Sheet | Alamy image

More from Complete Response Letters

More from Product Reviews